[Severe infections caused by methicillin-resistant Staphylococcus aureus. 62 cases]

Area of Science:

• Infectious Diseases
• Bacteriology
• Epidemiology

Background:

• Severe staphylococcal infections pose a significant public health challenge.
• Nosocomial infections are a major contributor to staphylococcal infections.
• Previous antibiotic use is common in patients with severe staphylococcal infections.

Purpose of the Study:

• To investigate the epidemiological, clinical, and therapeutic aspects of severe staphylococcal infections.
• To analyze the antibiotic resistance patterns of Staphylococcus aureus strains, including methicillin-resistant strains.
• To evaluate treatment outcomes and identify risk factors for severe outcomes.

Main Methods:

• A French multicentre study collected 347 cases of severe staphylococcal infections over one year.
• Bacteriological analysis was performed on 258 strains, including 62 methicillin-resistant Staphylococcus aureus (MRSA) strains.
• Epidemiological data, clinical presentations, and therapeutic interventions were recorded and analyzed.

Main Results:

• Nosocomial infection accounted for 90% of cases, with invasive procedures (catheters, ventilation, surgery) implicated in 69% of patients.
• MRSA strains exhibited high resistance to gentamicin, quinolones, clindamycin, and rifampicin.
• No resistance to glycopeptides (vancomycin, teicoplanin) was observed in the studied strains.
• Treatment with glycopeptides, alone or in combination, was utilized in 39 patients.
• The overall mortality rate was 35%, indicating a severe prognosis.

Conclusions:

• Severe staphylococcal infections, especially MRSA, are frequently hospital-acquired and associated with invasive procedures.
• Glycopeptides are effective against multidrug-resistant MRSA strains.
• Educational and prophylactic measures are crucial in high-risk medical departments to reduce the burden of these infections.